Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Bio-Techne ( (TECH) ).
Bio-Techne Corporation announced on February 11, 2026, that Dr. Matt McManus will transition from his role as President of the Diagnostics and Spatial Biology Segment effective March 1, 2026, after helping optimize the organization, including leading the strategic divestiture of the Exosome business. The board approved his termination without cause on February 9, 2026, and he will receive severance benefits in line with his employment agreement.
Effective March 1, 2026, Steve Crouse, currently Senior Vice President of Bio-Techne’s Analytical Solutions Division, will assume the role of President of the Diagnostics and Spatial Biology Segment, bringing over two decades of life sciences leadership and a record of strong growth and successful product launches. His executive employment agreement, signed February 10, 2026, sets out a $505,000 base salary, performance-linked cash incentives and substantial time- and performance-based equity awards, underscoring the strategic importance of the diagnostics and spatial biology business to Bio-Techne’s next phase of growth.
The most recent analyst rating on (TECH) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Bio-Techne stock, see the TECH Stock Forecast page.
Spark’s Take on TECH Stock
According to Spark, TipRanks’ AI Analyst, TECH is a Neutral.
Overall score reflects pressured recent operating performance (declining TTM revenue and margin compression) partly offset by a strong balance sheet and positive cash generation. Technicals are supportive with the stock trending above key moving averages, but valuation is a major drag given the very high P/E and low yield. Earnings call guidance suggests timing-related headwinds should ease with continued margin improvement, supporting a mid-range score.
To see Spark’s full report on TECH stock, click here.
More about Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostic markets. Its extensive portfolio, which supports biological research, drug discovery and clinical testing, generated more than $1.2 billion in net sales in fiscal 2025, and the company employs about 3,100 people worldwide.
Average Trading Volume: 2,054,743
Technical Sentiment Signal: Buy
Current Market Cap: $10.24B
For detailed information about TECH stock, go to TipRanks’ Stock Analysis page.